A pilot study on the combined therapy with GM-CSF and hepatitis B vaccine in intrauterine infected chronic Hepatitis B carrier children

王建设,朱启鎔,俞蕙,张婷

DOI: https://doi.org/10.3760/j.issn:0578-1310.2002.07.009

2002-01-01

Abstract:Objective To observe the efficacy of combined therapy with granulocyte macrophage colony stimulating factor (GM CSF) or hepatitis B immunoglobulin (HBIG) plus recombinant hepatitis B vaccine (rHBvac) in chronic hepatitis B carrier children. Methods Twenty seven chronic HBV carrier children, who were infected from chronic HBV carrier mothers in uterus and received HBvac or HBvac plus HBIG prophylaxis at birth, entered the study. After baseline serum samples were obtained and their alanine transaminase (ALT) levels were determined, they were randomized into two groups. Fourteen children were assigned to GM CSF group and received combined therapy with 50 μg of GM CSF plus 10 μg of rHBvac injected intramuscularly at same point. Thirteen children were assigned to HBIG group and receiving 200 μg HBIG and 10 μg intramuscular rHBvac injections at different sites. Both regimens were applied with a four dose schedule at one month interval. One month after the fourth injection, the post treatment serum sample was collected to test HBV DNA quantification and other HBV serological markers with the baseline sample at the same time. Results All subjects completed the four dose schedule, no adverse events were reported in either group. Two children in GM CSF group and one in HBIG group dropped off the study since the parents refused to have blood specimens taken after the treatment. Therefore, 12 children in either group were further analyzed. Before the trial, 3 children in GM CSF group had slightly elevated serum ALT (80 U/L), and 4 in HBIG group had elevated serum ALT (41 80 U/L in 3,180 U/L in 1). Among them, 2 in each group became ALT normal after the treatment. Before the therapy, HBeAg positivity was found in 9 children of GM CSF group and 10 of HBIG group, 1 in each group had an HBeAg/anti HBe seroconvertion after the treatment. Before the treatment, all subjuects were HBV DNA positive in GM CSF group, 11 positive in HBIG group. After the treatment, 3 children became HBV DNA negative, 2 others had sharply decreased serum HBV DNA (less than 1/10 of the baseline) in GM CSF group; One child became HBV DNA negative in HBIG group, with HBeAg/anti HBe seroconvertion. The quantity of HBV DNA was significantly lower after the treatment than before ( P =0.023) in GM CSF group, the quantity of HBV DNA was not significantly reduced in HBIG group. No subjects were found negative for HBsAg after the treatment. Conclusion Combined GM CSF and rHBvac therapy inhibit the levels of HBV replication in carrier children who were not protected by immunoprophylaxis.